Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
From neuropsychiatric use to oncology: Repurposing antipsychotic drugs for cancer treatment.
Quality by design (QbD)-driven formulation of sildenafil citrate microparticles using quasi-emulsion technique for pulmonary delivery: an <i>in vitro</i> study.
Related Experiment Video
Updated: May 7, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Smart Immunoliposome-Based Targeted Drug Delivery for Cancer: A Comprehensive Systematic Review.
Gandhali Ghaisas1, Vaishali Y Londhe1
1Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai, Maharashtra, India.
Immunoliposomes, antibody-modified nanoparticles, offer improved cancer treatment by precisely targeting tumors and minimizing side effects. This review explores advances in immunoliposome engineering for enhanced cancer therapy.
Area of Science:
- Nanotechnology
- Oncology
- Drug Delivery Systems
Background:
- Cancer chemotherapy faces limitations due to severe systemic side effects.
- Targeted drug delivery, especially monoclonal antibody therapies, enhances treatment specificity.
- Liposomes are effective nanocarriers for diverse drug types, improving pharmacokinetics and drug release.
Purpose of the Study:
- To review recent advancements in immunoliposome engineering.
- To evaluate immunoliposome performance in various cancer models.
- To highlight the potential of immunoliposomes in transforming targeted cancer therapy.
Main Methods:
- Systematic review conducted following PRISMA guidelines.
- Analysis of diverse strategies for conjugating monoclonal antibodies to liposomes.
- Evaluation of intrinsic and extrinsic stimuli-responsive immunoliposome designs.
Main Results:
- Immunoliposomes represent a next-generation liposomal therapeutic.
- Established strategies exist for antibody conjugation to liposomal surfaces.
- Stimuli-responsive designs enable site-selective drug delivery.
Conclusions:
- Immunoliposomes show significant promise for targeted cancer treatment.
- Engineering advances are refining immunoliposome efficiency and specificity.
- Further evaluation across cancer models underscores their therapeutic potential.

